While statins show moderate promise for colorectal cancer (CRC) chemoprevention, especially in subtypes characterized by SMAD4 positivity, APC mutations, or KRAS-driven pathways, the evidence is not yet sufficient to recommend their clinical use. This evidence concerns the gene SMAD4 and colorectal carcinoma.